These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38301858)

  • 1. FBXO8 is a novel prognostic biomarker in different molecular subtypes of breast cancer and suppresses breast cancer progression by targeting c-MYC.
    Khan AJ; Man S; Abbas M; Liu S; Zhang F
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130577. PubMed ID: 38301858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
    Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.
    Shen Y; Xue J; Yu J; Jiang Y; Bu J; Zhu T; Gu X; Zhu X
    World J Surg Oncol; 2022 Dec; 20(1):398. PubMed ID: 36517818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Knockdown of IGF2BP2 inhibits colorectal cancer cell proliferation, migration and promotes tumor immunity by down-regulating MYC expression].
    Liu T; Han C; Hu C; Mao S; Sun Y; Yang S; Yang K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Apr; 39(4):303-310. PubMed ID: 37087547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
    Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
    Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
    Liu Y; Zhu C; Tang L; Chen Q; Guan N; Xu K; Guan X
    Int J Biol Sci; 2021; 17(1):178-187. PubMed ID: 33390842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients.
    Ibusuki M; Yamamoto Y; Shinriki S; Ando Y; Iwase H
    Cancer Sci; 2011 Feb; 102(2):439-45. PubMed ID: 21134077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FBX8 Acts as an Invasion and Metastasis Suppressor and Correlates with Poor Survival in Hepatocellular Carcinoma.
    Wang F; Qiao Y; Yu J; Ren X; Wang J; Ding Y; Zhang X; Ma W; Ding Y; Liang L
    PLoS One; 2013; 8(6):e65495. PubMed ID: 23826080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FBXW7 circular RNA regulates proliferation, migration and invasion of colorectal carcinoma through NEK2, mTOR, and PTEN signaling pathways in vitro and in vivo.
    Lu H; Yao B; Wen X; Jia B
    BMC Cancer; 2019 Sep; 19(1):918. PubMed ID: 31519156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma.
    Li Z; Xiao J; Hu K; Wang G; Li M; Zhang J; Cheng G
    Int J Mol Sci; 2015 Jan; 16(2):2294-306. PubMed ID: 25622249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
    AlSultan D; Kavanagh E; O'Grady S; Eustace AJ; Castell A; Larsson LG; Crown J; Madden SF; Duffy MJ
    Invest New Drugs; 2021 Apr; 39(2):587-594. PubMed ID: 33052557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop.
    Zhao X; Shu D; Sun W; Si S; Ran W; Guo B; Cui L
    Cancer Commun (Lond); 2022 Oct; 42(10):987-1007. PubMed ID: 36002342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer.
    Lorentzen A; Lewinsky RH; Bornholdt J; Vogel LK; Mitchelmore C
    BMC Cancer; 2011 Jan; 11():14. PubMed ID: 21226903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of c-Myc-RBM38 loop in the growth suppression in breast cancer.
    Li XX; Shi L; Zhou XJ; Wu J; Xia TS; Zhou WB; Sun X; Zhu L; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2017 Apr; 36(1):49. PubMed ID: 28399911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
    Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
    Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
    Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
    Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.